Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-03-17
1996-03-19
Walsh, Stephen G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 56, 514838, 530399, A61K 3818
Patent
active
055004091
ABSTRACT:
A composition for the treatment of skin fibrotic and other cirrhotic diseases comprising an endothelial cell growth factor, either alone or in combination with heparin or a heparin-like compound is provided. Methods for the treatment of skin fibrotic and other cirrhotic diseases and for inhibition of collagen synthesis by skin fibroblasts using an endothelial cell growth factor either alone or in combination with heparin or a heparin-like compound are also provided.
REFERENCES:
patent: 4745098 (1988-05-01), Michaeli
patent: 4760131 (1988-06-01), Sundsmo et al.
patent: 4808570 (1989-02-01), Michaeli
patent: 4837024 (1989-06-01), Michaeli
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 4883755 (1989-11-01), Carabasi et al.
patent: 4889808 (1989-12-01), Rappaport
patent: 4950483 (1990-08-01), Ksander et al.
patent: 5026839 (1991-06-01), Moscatelli et al.
patent: 5120715 (1992-06-01), Kato et al.
patent: 5155214 (1992-10-01), Baird et al.
patent: 5189148 (1993-02-01), Akiyama et al.
Sigma Chemical Company Catalog, p. 444 (1990).
Burgess et al., "Structural evidence that endothelial cell growth factor .beta. . . . ", PNAS 83:7216-7220 (Oct. 1986).
Turck et al. (1989), Immunology, vol. 68: pp. 410-415.
Finesmith et al. (1990) Journal of Cellular Physiology. vol. 144: pp. 99-107.
Odedra et al. (1987) Biochemical and Biophysical Research Communications vol. 143, No. 3, pp. 947-953.
Broadley et al. (1988) Int. J. Tiss. Reac. vol. 6: pp. 345-353.
Buckley-Sturrock et al. (1989) Journal of Cellular Physiology, vol. 138: pp. 70-78.
Kelly, A. P. Keloids, Dermatol. Clin. 6:413-424, (1988).
Berman, B., and M. R. Duncan, "Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro", J. Am. Acad. Dermatol. 21:694-702 (1989).
Panabiere-Castaings, M. H., "Retinoic acid in the treatment of keloids", J. Dermatol. Surg. Oncol., 14: 1275-1276 (1988).
Daly, T. J., and W. L. Weston, "Retinoid effects on fibroblast fibrotic disease in vivo", J. Am. Acad. Dermatol., 15:900-902 (1986).
Clowes A. W., and M. J. Karnovsky, "Suppression by heparin of smooth muscle cell proliferation in injured arteries", Nature 265:625-626 (1977).
Castellot, J. J. Jr., A. M. Kambe, D. E. Dobson, and B. M. Spiegelman, "Herparin potentiation of 3T3-adipocyte stimulated angiogenesis: mechanisms of action of endothelial cells", J. Cell Physiol., 127:323-329 (1986).
Ehrlich, H. P., W. K. Jung, D. E. Costa, and J. B. M. Rajaratnam, "Effects of heparin on vascularization of artificial skin grafts in rats", Exp. Molec. Pathol., 48:244-251 (1988).
Joseph-Silverstein, J. and D. B. Rifkin, "Endothelial cell growth factors", Semin. Thromb. Hemost., 13:504-513 (1987).
Brown, C. C. and G. Balian, "Effect of heparin on synthesis of short chain collagen by chondrocytes and smooth muscle cells" J. Cell Biol., 99:1688-1695 (1987).
Graham, M. T., D. E. Drucker, H. A. Perr, R. F. Diegelmann, H. P. Ehrlich, "Heparin modulates human intestinal smooth muscle cell proliferation, protein synthesis and lattice contraction", Gastroenterology 93:801-809 (1987).
Lyons-Giordano, B., H. Conaway, and N. A. Kefalides, "The effect of heparin on fibronectin and thrombospondin synthesis by human smooth muscle cells", Biochem. Biophys. Res. Commun., 148:1264-1269 (1987).
Damon, D. H. et al. "Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half-life", J. Cell. Physiol.).
Thornton, S. C., S. N. Mueller, and E. M. Levine, "Human endothelial cells: use of heparin in cloning and long-term serial cultivation", Science, 222:623-625 (1983).
Maciag, T., T. Mehlman, and R. Friesel, "Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain", Science, 225:932-935 (1984).
Gospodarowicz, D. and J. Cheng, "Heparin protects basic and acidic fibroblast growth factor from inactivation", J. Cell. Physiol., 475-484 (1986).
Shreiber, A. B. et al. "The interaction of endothelial cell growth factor with heparin", Proc. Natl. Acad. Sci. USA, 82:6138-6142, (1985).
Tan, E. M. L. et al. "Heparin and endothelial cell growth factor modulate collagen proteoglycan production in human smooth muscle cells", Biochem. Biophys. Res. Commun., 163:84-92 (1989).
Juva, K. and D. J. Prockop, "Modified procedure for the assay of H.sup.3 - or C.sup.14 -labeled hydroxyproline", Anal. Biochem. 15:77-83 (1966).
Bradford, M. M., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding" Anal. Biochem., 72:248-254 (1976).
Burton, K., "Determination of DNA concentration with diphenylamine", Methods Enzymol. 12B:163-166 (1968).
Oikarinen, H., A. l. Oikarinen, E. M. L. Tan, R. P. Abergel, "Modulation of procollagen gene expression by retinoids", J. Clin. Invest., 75:1545-1553 (1985).
Maniatis, T., A. Jeffrey, and D. G. Kleid, "Nucleotide sequence of the rightward operator of phage" Proc. Natl. Acad. Sci. USA, 72:1184-1188 (1975).
Uitto, J. et al. "Altered steady-state ratio of type I/type III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts", Proc. Natl. Acad. Sci. USA, 82:5935-5939 (1985).
Thomas, P. S., "Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose", Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980).
Chu, M. L., J. C. Myers, M. P. Bernard, D. F. Ding, and F. Ramirez, "Cloning and characterization of the five overlapping cDNAs specific for the human pro-alpha 1(I) collagen", Nucleic Acids Res., 10:5925-5934 (1982).
Bernard, M. P., M. Kolbe, D. Weil, and M. L. Chu, "Human cellular fibronectin: comparison of the carboxyl-terminal portion with rat identified primary structural domain separated by hypervariable regions" Biochemistry, 24:2698-2704 (1985).
Ponte, P. et al. "Human actin genes are single copy for alpha-skeletal and alpha-cardiac actin but multicopy for beta- ad gamma-cytoskeletal genes: 3' untranslated regions are isotype specific but are conserved in evolution", Mol. Cell. Biol., 3:1783-1791 (1983).
Tan Elaine M. L.
Uitto Jouni J.
Licata Jane Massey
Thomas Jefferson University
Walsh Stephen G.
LandOfFree
Method for inhibiting collagen synthesis by keloid fibroblasts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting collagen synthesis by keloid fibroblasts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting collagen synthesis by keloid fibroblasts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1959350